Profile data is unavailable for this security.
About the company
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
- Revenue in USD (TTM)0.00
- Net income in USD-28.08m
- Incorporated2018
- Employees13.00
- LocationMaia Biotechnology Inc444 West Lake StreetSuite 1700, Suite 1700CHICAGO 60606United StatesUSA
- Phone+1 (312) 416-8592
- Fax+1 (302) 655-5049
- Websitehttps://maiabiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| VolitionRX Ltd | 976.52k | -32.42m | 63.89m | 110.00 | -- | -- | -- | 65.43 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Atara Biotherapeutics Inc | 62.39m | -181.05m | 64.05m | 165.00 | -- | -- | -- | 1.03 | -39.90 | -39.90 | 13.06 | -22.61 | 0.343 | 0.931 | 42.60 | 277,275.60 | -99.55 | -70.20 | -256.98 | -86.94 | 80.14 | -- | -290.20 | -1,559.33 | 0.2945 | -250.76 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Prelude Therapeutics Inc | 3.00m | -131.52m | 65.49m | 128.00 | -- | 0.3209 | -- | 21.83 | -1.77 | -1.77 | 0.0404 | 3.71 | 0.0132 | -- | -- | 23,437.50 | -57.72 | -47.21 | -63.14 | -51.07 | -- | -- | -4,383.90 | -- | -- | -- | 0.0023 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Vor Biopharma Inc | 0.00 | -118.09m | 65.53m | 168.00 | -- | 0.6677 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -28.08m | 69.57m | 13.00 | -- | 21.85 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 70.03m | 68.00 | -- | -- | -- | 181.43 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Spero Therapeutics Inc | 118.46m | 17.46m | 71.34m | 46.00 | 4.17 | 0.8856 | 4.05 | 0.6023 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Allovir Inc | 0.00 | -140.34m | 71.41m | 112.00 | -- | 0.5934 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.00m | 72.47m | 68.00 | -- | 0.7528 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -53.12m | 73.57m | 32.00 | -- | 1.57 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 74.37m | 22.00 | -- | 0.8679 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.16m | 75.04m | 13.00 | -- | 1.31 | -- | 75.04 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Metagenomi Inc | 55.93m | -75.00m | 75.68m | 228.00 | -- | 0.2809 | -- | 1.35 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -171.44m | 76.37m | 74.00 | -- | 0.4774 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Data as of Nov 09 2024. Currency figures normalised to Maia Biotechnology Inc's reporting currency: US Dollar USD
7.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Halter Ferguson Financial, Inc.as of 30 Jun 2024 | 721.67k | 3.02% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 537.02k | 2.25% |
| Geode Capital Management LLCas of 30 Jun 2024 | 156.74k | 0.66% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 75.82k | 0.32% |
| Centric Wealth Management LLCas of 30 Jun 2024 | 68.20k | 0.29% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 45.70k | 0.19% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 34.40k | 0.14% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 32.07k | 0.13% |
| Naviter Wealth LLCas of 30 Sep 2024 | 22.17k | 0.09% |
| Verition Fund Management LLCas of 30 Jun 2024 | 15.37k | 0.06% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
